GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at H... ( GenOdyssee has Received Notice of...)

GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C

Date:2/14/2008

GenOdyssee has Received Notice of Allowance of United States Patent Application Covering its Lead HCV Interferon-alpha Product GEA007.1, a

Natural Protein With Improved Anti-HCV Genotype 1 Activity

PARIS, France, February 14 /PRNewswire/ -- GenOdyssee S.A., a biotechnology company dedicated to the discovery and development of improved 'next generation' blockbuster protein therapeutic products, announced today that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) of its Patent Application Ndegrees 10/691,653 covering its lead anti-HCV IFN-alpha product GEA007.1 for application in the treatment of hepatitis C. GEA007.1 is a naturally occurring mutant of human IFN alpha 17. In preclinical studies, GEA007.1 demonstrated improved intrinsic anti-genotype 1 antiviral properties without increased toxicity at therapeutic doses used in HCV treatments, as compared to standard of care IFN-alpha 2 drugs.

"We are very happy with this notice of allowance, which represents an important milestone for us. Combined with the granting in the European Union in 2006 of our patent application covering GEA007.1, this is a proof-of-concept of the global standard of innovation set by our lead HCV program," said Jean-Louis Escary, Ph.D., CEO of GenOdyssee. Similar to the European Patent Office notice of allowance report on this product that was issued in 2006, the current USPTO notice of allowance report did not reveal any prior art references relevant to the invention constituted by GEA007.1.

A recent communication with the USPTO revealed that GenOdyssee's patent application covering a second lead IFN-alpha drug candidate, GEA009.2, to be used in cancer, is expected to be allowed in the United States in the near future. "This confirms the uniqueness of GenOdyssee's proprietary technology as well as our global leadership position in the interferon arena," said Dr. Escary. "Our technology has also proven to
'/>"/>

SOURCE GenOdyssee SA
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Quintiles Central Laboratory in India Receives CAP Certification
2. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
3. Photo: Animal Rescue League of Boston Receives $3 Million Grant to Establish a Center for Shelter Dogs
4. Stereotaxis Receives $20 Million in Additional Loan Commitments
5. MedApps Receives Prestigious Frost & Sullivan Award
6. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
7. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
8. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
9. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
10. Regions Hospital Receives National Quality Awards
11. Laser Energetics Receives a $550,000 Order for a Dental Laser System

Post Your Comments:

(Date:5/22/2013)... Researchers in genomic health disparities from the University ... University School of Medicine have teamed up to hold ... Eliminate Health Disparities in Genomic Medicine." The theme ... nonprofits, business and government to reduce these disparities. , ... United States, individuals within underserved groups continue to be ...

(Date:5/22/2013)... By Maureen Salamon HealthDay Reporter , , WEDNESDAY, ... each cause a great deal of suffering, but new ... linked to something else entirely -- a smaller brain. ... double the risk of depression, scientists wanted to determine ... The difference in size -- about 2 percent -- ...

(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...

(Date:5/22/2013)... May 22, 2013 Recent tragedies ... and the school shooting in Newtown, Connecticut all ... , Emergency medical practitioners train to ... the Emergency Medical Services for Children (EMSC) Program ... care for the youngest patients. It is estimated ...

(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...

Breaking Medicine News(10 mins):Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 2 Health News:Having Both Migraines, Depression May Mean Smaller Brain 3 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2 Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3 Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2 Health News:How To "Make Your Own Healthy Energy Bars" 2

[0] Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine [0] Having Both Migraines, Depression May Mean Smaller Brain [0] Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year”[0] When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care [0] How To "Make Your Own Healthy Energy Bars"

... World Health Organization expected to make recommendation next week, ... Vaccine manufacturers and other health experts met Thursday at ... plot potential strategies to combat the swine flu virus ... infection worldwide. , The Associated Press reported ...

... In conjunction with CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, ... Internet on Thursday, June 4th at 11:30 am Eastern Time., Event: ... Hosted by: Dan Starck, President and CEO, ... Chairman, Date: 11:30 am ...

... OAK BROOK, Ill. May 14, 2009 In ... Barrett,s esophagus, electronic diagnosis overestimated the prevalence of the ... only 61.9 percent of patients assigned a billing diagnosis ... a manual record review. The study evaluated the accuracy ...

... country join forces to advocate for more research funding ... we continue to mark Food Allergy Awareness Week, Robert ... of the Food Allergy Initiative (FAI), announced the formation ... are to help build a strong nationwide presence for ...

... May 14 If the H1N1 pandemic flu follows the ... with more vigor in a second wave next fall. In ... unusual rapidity, resulting in 3 explosive pandemic waves within a ... for the Prudent Use of Antibiotics and Microbiology Lab Director ...

... of life over 8 years of follow-up, study finds, ... (ICDs) extend heart patients, lives even eight years after ... be presented Thursday at the Heart Rhythm Society annual ... ICD therapy, sustained for over eight years, does in ...

Health Experts Plot Strategy for Swine Flu Vaccine CorVel Announces Fiscal Year Earnings Release Webcast Study examines reliability of clinical and pathological diagnoses of Barrett's esophagus Robert F. Kennedy, Jr. Announces New Food Allergy Initiative Advocacy Steering Committee H1N1 Pandemic Precautions for Front Line Workers Implanted Defibrillators Boost Long-Term Survival

(Date:5/22/2013)... YORK , May 22, 2013 ... investigating potential claims on behalf of purchasers of ... the "Company") (NasdaqGS: AMAG -News). The investigation focuses ... federal securities laws. On May 22, ... during intraday trading after the company announced in ...

(Date:5/22/2013)... WHITE PLAINS, N.Y. , May 22, 2013 /PRNewswire/ ... $6 million to Valor Biotherapeutics, LLC, a ... completion of pre-clinical development, manufacturing, and a Phase I ... change the poor outcomes faced by many patients with ... with rituximab. Valor,s protein, IGN002, is ...

(Date:5/22/2013)... NEW YORK , May 22, 2013 The ... international conference devoted to advancing new treatments for lupus ... to 60 percent of patients. The conference launched a ... – the Lupus Nephritis Trials Network (LNTN). ... lupus and the kidney came together to focus on ...

Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4 Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2

[0] Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.[0] The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients [0] Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis

... N.J., Sept. 29 Sparta Systems, Inc. ... software and the market leader in enterprise ... Qualitest Pharmaceuticals , a top-six provider of ... streamline multiple quality and compliance processes. ...

... China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...

Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Doxepin, Urine Drinox, Serum Dramamine, Urine Doxycycline, Antimicrobial (Serum or Body Fluid) Level, BA